Human leukocyte antigen A3-restricted melanoma-associated peptide (HLA-A3 melanoma peptide)

HLA-A3-restricted melanoma-associated peptides are short amino acid sequences derived from proteins highly expressed in melanoma cells, such as gp100, tyrosinase, and MAGE-A3, which are presented on the cell surface by the Human Leukocyte Antigen A3 (HLA-A3) class I molecule (Skipper et al., 1996; Kawashima et al., 1998). These peptide-MHC complexes act as specific flags that enable the immune system, particularly CD8+ cytotoxic T lymphocytes, to identify and eliminate cancerous cells (NIH/NCI). Because HLA-A3 is one of the more common HLA alleles in certain populations, these peptides represent significant targets for personalized cancer immunotherapy. Therapeutic approaches targeting these complexes include peptide-based vaccines designed to stimulate endogenous T-cell responses and adoptive T-cell therapies (TCR-T) that utilize engineered receptors to recognize the HLA-A3/peptide complex (PubMed). The success of these therapies is contingent upon the patient's HLA-A3 status and the consistent expression of the source antigen within the tumor. However, challenges such as tumor-mediated HLA downregulation and the potential for cross-reactivity with healthy tissues, leading to autoimmunity like vitiligo, remain significant hurdles in clinical development (StatPearls).

Other names

HLA-A*03-restricted melanoma antigenHLA-A3-restricted melanoma epitopeMelanoma-associated antigen peptide presented by HLA-A3HLA-A*0301 restricted melanoma peptide

Activation of antigen-specific CD8+ T cells via T-cell receptor (TCR) recognition of the peptide-MHC complex